Cytokine-induced killer cells promote antitumor immunity

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Jiang, Jingting ^a   Wu, Changping ^a   Lu, Binfeng ^b  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL ACTIVITY; CELL FUNCTION; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CELL TRANSFER; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; GENETIC ENGINEERING; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE FUNCTION; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR IMMUNITY;

ANIMALS; BLOOD COMPONENT REMOVAL; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, SCID; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875282081     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-83     Document Type: Review

References (80)

1. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011, 9:214. 10.1186/1479-5876-9-214, 3338100, 22168571.
2. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011, 71:5601-5605. 10.1158/0008-5472.CAN-11-1316, 21846822.
3. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 1955, 102:157-177. 10.1084/jem.102.2.157, 2136501, 13242741.
4. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557. 10.1158/1078-0432.CCR-11-0116, 3131487, 21498393.
5. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321. 10.1126/science.3489291, 3489291.
6. Yron I, Wood TA, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 1980, 125:238-245.
7. Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol 1980, 125:1487-1493.
8. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984, 225:1487-1489. 10.1126/science.6332379, 6332379.
9. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011, 17:6287-6297. 10.1158/1078-0432.CCR-11-1347, 3186830, 21844012.
10. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981, 41:4420-4425.
11. Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol 1987, 138:2728-2733.
12. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991, 174:139-149. 10.1084/jem.174.1.139, 2118875, 1711560.
13. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993, 21:1673-1679.
14. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:181-187. 10.1016/j.bbmt.2004.11.019, 15744236.
15. Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008, 20:841-848. 10.1093/intimm/dxn042, 18469328.
16. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153:1687-1696.
17. Silva MR, Parreira A, Ascensao JL. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion. Exp Hematol 1995, 23:1676-1681.
18. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998, 92:3318-3327.
19. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002, 116:78-86. 10.1046/j.1365-2141.2002.03247.x, 11841399.
20. Hongeng S, Petvises S, Worapongpaiboon S, Rerkamnuaychoke B, Pakakasama S, Jootar S. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 2003, 77:175-179. 10.1007/BF02983217, 12627854.
21. Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, Du QY, Chen JM. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 2002, 8:464-468.
22. Sun S, Li XM, Li XD, Yang WS. Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm 2005, 20:173-180. 10.1089/cbr.2005.20.173, 15869451.
23. Kim HM, Lim J, Park SK, Kang JS, Lee K, Lee CW, Lee KH, Yun MJ, Yang KH, Han G. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 2007, 7:1802-1807. 10.1016/j.intimp.2007.08.016, 17996691.
24. Wang P, Yu JP, Gao SY, An XM, Ren XB, Wang XG, Li WL. Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells. Cell Immunol 2008, 253:59-65. 10.1016/j.cellimm.2008.04.014, 18522858.
25. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001, 7:532-542. 10.1016/S1083-8791(01)70014-6, 11760085.
26. Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 1995, 86:3493-3499.
27. Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310. 10.1182/blood-2011-02-336321, 21821703.
28. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001, 294:605-609. 10.1126/science.1063916, 11567106.
29. Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol 2005, 175:7819-7828.
30. Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf IG. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?. Leuk Res 2011, 35:1136-1142. 10.1016/j.leukres.2011.05.005, 21652069.
31. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001, 97:2923-2931. 10.1182/blood.V97.10.2923, 11342413.
32. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003, 101:640-648. 10.1182/blood-2002-06-1751, 12393519.
33. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999, 81:1009-1016. 10.1038/sj.bjc.6690800, 2362953, 10576658.
34. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, Nilsson-Ehle P. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 2006, 26:2237-2242.
35. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952-959. 10.3324/haematol.11132, 17606446.
36. Wu C, Jiang J, Shi L, Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008, 28:3997-4002.
37. Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009, 41:36-41. 10.1016/j.dld.2008.04.007, 18818130.
38. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009, 27:130-139. 10.1002/hon.886, 19294626.
39. Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX, Chen LJ, Zheng X, Sun J, Lu BF, Zhang XG. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 2010, 16:6155-6162. 10.3748/wjg.v16.i48.6155, 3012571, 21182234.
40. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1679-1687. 10.1016/j.bbmt.2011.05.012, 3175285, 21664472.
41. Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012, 18:1751-1759. 10.1158/1078-0432.CCR-11-2442, 22275504.
42. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011, 137:305-310. 10.1007/s00432-010-0887-7, 20407789.
43. Li X, Xu B, Wu J. Review of Chinese clinical trial trials on CIK cell treatment for malignancies. Clin Transl Oncol 2012, 14:242-245.
44. Zoll B, Lefterova P, Ebert O, Huhn D, Von Ruecker A, Schmidt-Wolf IG. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine 2000, 12:1385-1390. 10.1006/cyto.2000.0733, 10975999.
45. Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, Huang K, Zhou DH. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res 2010, 30:3493-3499.
46. Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2011, 6:6.
47. Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, Micka B, Roigk K, Fehlinger M, Schmidt-Wolf GD. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 1998, 47:221-226. 10.1007/s002620050524, 9875675.
48. Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 2010, 59:1325-1334. 10.1007/s00262-010-0860-y, 20532883.
49. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378:88-91. 10.1038/378088a0, 7477296.
50. Yang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, Zhang X, Finn OJ, Chen X, Lu B. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol 2011, 41:3351-3360. 10.1002/eji.201141629, 3332117, 21887788.
51. Gold JE, Ross SD, Krellenstein DJ, LaRosa F, Malamud SC, Osband ME. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur J Cancer 1995, 31A:698-708.
52. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012, 11:215-233. 10.1038/nrd3626, 22301798.
53. Butterfield LH, Vujanovic L. New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Curr Opin Investig Drugs 2010, 11:1399-1408.
54. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577. 10.1126/science.1208347, 22174255.
55. Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med 2012, 10:48. 10.1186/1479-5876-10-48, 3362772, 22420641.
56. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129. 10.1126/science.1129003, 2267026, 16946036.
57. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546. 10.1182/blood-2009-03-211714, 2929689, 19451549.
58. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29:917-924. 10.1200/JCO.2010.32.2537, 3068063, 21282551.
59. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102. 10.1182/blood-2010-04-281931, 2993617, 20668228.
60. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73. 10.1126/scitranslmed.3002842, 3393096, 21832238.
61. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828. 10.1182/blood-2011-04-348540, 3208293, 21849486.
62. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011, 8:8.
63. Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 2006, 12:1859-1867. 10.1158/1078-0432.CCR-05-2019, 16551871.
64. Thakur A, Lum LG. Cancer therapy with bispecific antibodies: clinical experience. Curr Opin Mol Ther 2010, 12:340-349.
65. Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011, 11:843-853. 10.1517/14712598.2011.572874, 21449821.
66. Dugast AS, Haudebourg T, Coulon F, Heslan M, Haspot F, Poirier N, Vuillefroy de Silly R, Usal C, Smit H, Martinet B. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008, 180:7898-7906.
67. Haymaker C, Wu R, Bernatchez C, Radvanyi L. PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. Oncoimmunology 2012, 1:735-738. 10.4161/onci.20823, 3429577, 22934265.
68. Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. J Immunother 2012, 35:579-586. 10.1097/CJI.0b013e31826b1fd9, 22892454.
69. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006, 311:1780-1784. 10.1126/science.1121411, 16556847.
70. Tang D, Kang R, Livesey KM, Zeh HJ, Lotze MT. High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal 2011, 15:2185-2195. 10.1089/ars.2010.3666, 3166205, 21395369.
71. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011, 17:654-666. 10.1158/1078-0432.CCR-10-2634, 3075808, 21325294.
72. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ, Lotze MT. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010, 190:881-892. 10.1083/jcb.200911078, 2935581, 20819940.
73. Rettinger E, Meyer V, Kreyenberg H, Volk A, Kuci S, Willasch A, Koscielniak E, Fulda S, Wels WS, Boenig H. Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front Oncol 2012, 2:32. 3356002, 22655268.
74. Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res 2012, 18:5352-5363. 10.1158/1078-0432.CCR-12-0628, 22893632.
75. Sabbagh L, Kaech SM, Bourbonniere M, Woo M, Cohen LY, Haddad EK, Labrecque N, Ahmed R, Sekaly RP. The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol 2004, 173:5425-5433.
76. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, Gapin L, Kaech SM. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007, 27:281-295. 10.1016/j.immuni.2007.07.010, 2034442, 17723218.
77. Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest 2013, 123(2):594-599.
78. Lu B. The molecular mechanisms that control function and death of effector CD4+ T cells. Immunol Res 2006, 36:275-282. 10.1385/IR:36:1:275, 17337788.
79. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-1096.
80. Kobori H, Hashiguchi M, Piao J, Kato M, Ritprajak P, Azuma M. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites. Immunology 2010, 130:363-373. 10.1111/j.1365-2567.2009.03236.x, 2913216, 20141543.